aspen-03: evorpacept in combination with pembrolizumab in patients with advanced hnscc
Published 2 years ago • 124 plays • Length 2:03Download video MP4
Download video MP3
Similar videos
-
1:36
addition of an egfr/tgfβ inhibitor with pembrolizumab in head and neck cancer
-
1:05
dr. petrylak on combinations with pembrolizumab in urothelial carcinoma
-
3:08
improved survival, toxicity & qol with pembrolizumab in head and neck cancer
-
1:27
where to go next with pembrolizumab and other anti-pd-1 therapies in head and neck cancer
-
7:19
pembrolizumab yielded durable responses in patients with advanced merkel cell carcinoma
-
5:24
keynote048: first line pembrolizumab for r/m hnscc
-
2:13
nivolumab in hnscc
-
5:34
pembrolizumab for recurrent hnscc
-
2:26
sd-101 plus pembrolizumab for hnscc
-
5:16
pembrolizumab found to be safe with durable responses in advanced, non-small cell lung cancer
-
2:00
exploring the combination of epacadostat and pembrolizumab in urothelial carcinoma
-
2:38
enhanced pembrolizumab efficacy with ephb4-albumin in hpv-negative head and neck cancer | oncotarget
-
4:42
pembrolizumab for recurrent head and neck squamous cell carcinomas (hnscc)
-
0:58
dr. machiels on pembrolizumab in head and neck cancer
-
1:13
keynote-b84: pepinemab pembrolizumab for metastatic/recurrent head & neck squamous cell carcinoma
-
1:17
dr. ferris on fda approval of nivolumab in patients with head and neck cancer
-
1:22
dr. gupta on phase ib/ii trial of pembrolizumab with bevacizumab in rcc
-
5:37
phase iii trial shows pembrolizumab preferable to ipilimumab in advanced melanoma
-
0:39
predicting responses to immunotherapy in head and neck cancer